Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of TQB2450 + paclitaxel/carboplatin followed by TQB2450 + anlotinib versus tislelizumab + paclitaxel/carboplatin in first-line advanced squamous NSCLC
CTR20223447Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart, anlotinib, tislelizumab, paclitaxel, carboplatin in Pulmonary squamous cell carcinoma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Feb 2023; status: active.
02
Drugs
benmelstobartanlotinibtislelizumabpaclitaxelcarboplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20223447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223447.